Ceapro Inc V.CZO

Failure, again.

[boazklinghorn]

Apparently there is no amount of failure that this board won't indulge. The language about a solid base business and slow ordering is gone so we can assume ten million is the new revenue run rate. Gilles had one thing and that was the reliable base business that he always claimed to have built, well that's gone. Now his tenure is literally one of is failure at every single step. And yet he still has a job, amazing.

[prophetoffactz]

"The language about a solid base business and slow ordering is gone so we can assume ten million is the new revenue run rate. Gilles had one thing and that was the reliable base business that he always claimed to have built, well that's gone." Just last month Gilles said at the presentation that he is confident 2024 will return to historical trends once the adjustment in 2023 have

[boazklinghorn]

If I had a dollar for everything Gilles said that eventually came to pass I would have ZERO EFFING DOLLARS. So I will take this latest statement with a bucket of salt. 

[boazklinghorn]

And the market is again voting with its feet and getting out of CZO at any price. 

[boazklinghorn]

Of course Gilles is hiding from analysts and shareholders as usual so there will be no additional details about anything. What an A whole 

[ZoranSto]

You just read my mid....

[ZoranSto]

Ohhh...Gilles says.....So we can believe him this time???? How about all the other times he has been wrong ..... so what Gilles says does not hold water anymore.

[Tencents]

In general 10 % of candidates get to market and this will probably be in 2035 - Gagnon says in 7 years - and also none of them might get there  With current r&d spend ( and relatively enormous admin spend) a cash crunch is probable end 2024  A major impulsion of different approachs seems necessary 

[prophetoffactz]

"In general 10 % of candidates get to market and this will probably be in 2035 - Gagnon says in 7 years - and also none of them might get there" Avenanthramide has been tested in other human clinical trials and found safe. It is in oats. A synthetic analog of avenanthramide was approved in Japan with a strong safety profile. CZO has already run a human clinical trial with its

[prophetoffactz]

"In general 10 % of candidates get to market and this will probably be in 2035 - Gagnon says in 7 years - and also none of them might get there" Avalyn raised C$80 million going into its Phase I clinical trial. It just raised C$240 million going into its late stage trials. CZO's drug can work for fibrosis outside the lungs too and PGX-YBG ca be used to deliver other drugs or

[Tencents]

Indeed - true about Avalyn but note it took 13 years to get there and they have about 6 candidates in this area  Still have years to go to get a product in the market 

[prophetoffactz]

CZO's market cap is only C$20 million. Avalyn raised C$80 million going into its Phase I. What do you think Avalyn's market cap was going into Phase I given it raised C$80 million cash going into Phase I. CZO appears a short toxicology study away from declaring a Phase I clinical trial. CZO's drug also has the COVID opportunity which Avalyn didn't have when it raised C$80 million

[Tencents]

In general 10 % of candidates get to market and this will probably be in 2035 - Gagnon says in 7 years - and also none of them might get there With current r@d spend ( and relatively enormous admin spend) a cash crunch is probable end 2024 A major impulsion of different approachs seems necessary

[prophetoffactz]

CZO's avenanthramide and beta glucan for wound healing have already been tested in the gold standard model other companies use with the Angiogenesis Foundation. Gilles called the results a 'home run'. Dr. Li said the product could be like Intel Inside where the bioactives are used for a number of applications. Wound healing may have less risk than a drug used inside the body

[Ciao]

He "claimed" to have built but when asked in a webcast a few years ago, he admitted he did nothing to grow the base business (which is true). He's been on auto pilot for a decade and just dabbled in moving PGX through academia (no accountability) vs. engaging commercial partners (accountability for sure).

[PBaelishh]

...WHILE the PGX PATENT marches towards EXPIRING.  Is there even 3 years left on it?!! Anything developed with PGX now will be more of a gift to the industry as opposed to a gold mine for Ceapro.